Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

AbbVie's Alzheimer's Efforts Voyage Into AAV-Targeted Tau Antibodies

Feb 21 2018

• By Joseph Haas

MR image of Human brain

Related Content

Genzyme commits $100m upfront for Voyager's gene therapy expertise in CNS

Feb 12 2015

Voyager Cheers End Of Sanofi Partnership In Parkinson's; Investors Less Confident

Nov 01 2017

AbbVie Goes Boldly Into Immuno-Neurology With Alector

Oct 24 2017

Biogen Builds In Neurodegenerative Disease With Anti-Tau Deal

Apr 13 2017

Sanofi-Backed Voyager Therapeutics Hails Gene Therapy's Arrival

Aug 22 2017

Related Companies

AbbVie Inc.

Voyager Therapeutics, Inc

Biogen, Inc.

Bristol Myers Squibb Company

TauRx Therapeutics Ltd.

Alector, Inc.

Sanofi

California Institute of Technology

Additional Topics

Research & Development Deals Business Strategies Platform Technologies Neurology BioPharmaceutical

More from R&D

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window